Business
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilar
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Roivant Sciences","displaySize":"","headline":null,"caption":"Roivant Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/a57a72b6e3603bd6b96f169634edde44"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L2Xnap8Mf4WhlkU9YtDIfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4/https://media.zenfs.com/en/globenewswire.com/a57a72b6e3603bd6b96f169634edde44","width":300,"height":70},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/L2Xnap8Mf4WhlkU9YtDIfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4/https://media.zenfs.com/en/globenewswire.com/a57a72b6e3603bd6b96f169634edde44","width":300,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026","length":296,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":296,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026","length":253,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in non-infectious uveitis (NIU) is expected in the second half of calendar year 2026","length":226,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":226,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) is fully enrolled, with topline data expected in the second half of calendar year 2026; all other clinical development timelines remain on track","length":216,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":216,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content...